PRAX vs SUPN
PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms. SUPN: Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine while advancing a pipeline of novel neuropsychiatric therapies.
Side-by-side fundamentals
| Metric | PRAX | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $312.10 | $46.94 | |
| Market cap as of 2026-07-23 | $8.7B | $2.8B | |
| PEG as of 2026-07-23 | -0.95 | n/a | |
| Net margin as of 2026-07-23 | -2137.5% | -3.7% | SUPN higher |
| Gross margin as of 2026-07-23 | n/a | +89.7% | |
| Operating margin as of 2026-07-23 | -2340.3% | -7.8% | SUPN higher |
| ROE as of 2026-07-23 | -43.0% | -2.7% | SUPN higher |
| ROA as of 2026-07-23 | -40.2% | -2.0% | SUPN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +16.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.5% | |
| Beta as of 2026-07-23 | 2.80 | 0.57 | |
| 1-year return as of 2026-07-22 close | +476.3% | +43.7% | PRAX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.